A new class of drugs, known as PCSK9 inhibitors, has demonstrated the ability to lower LDL cholesterol levels by 50% to 66% in a variety of patient groups, according to clinical trials sponsored by such companies as Amgen, Sanofi, Regeneron and Pfizer, and presented at the annual meeting of the American College of Cardiology. If approved, PCSK9 inhibitors would be the first new cholesterol treatment to reach the market since the appearance of statins 25 years ago. Clinical outcomes are still needed to show whether lowering LDL will result in a reduction of cardiovascular events, such as stroke and heart attack.

Related Summaries